• 07/03/2021

Despite the COVID-19 pandemic, STADA has impressed with revenue growth of 18% and pre-tax profit of 15% in 2020, which thanks to effective investment and business strategies.

German pharmaceutical company is committed to bringing to the Vietnamese market pharmaceutical products as the same quality as Europe.

Growth during the pandemic

In the context of the COVID-19 pandemic causing many difficulties for the whole world, (Germany) STADA pharmaceutical company made an impression when we “go upstream” with revenue growth of up to 18%.

This result is the achievement of efforts accompanying the world health industry to combat against the COVID-19 pandemic during the past year of all officers – employees of the company.

“I’m proud of how the STADA team has worked tirelessly with hundreds of partners in the context of the pandemic, to continue providing medicine and communicate our purpose of taking care of everyone’s health as a reliable companion” – Mr. Peter Goldschmidt, CEO of STADA, shared.

Pre-tax profit increased by 15%

Not only has revenue increased sharply, but STADA’s profit has also grown impressively in the context of the pandemic. According to the company’s report, earning before interest, taxes, depreciation and amortization (EBITDA) increased 15% at constant exchange rates to EUR 713 million.

This is the ombination result of acquisitions, as well as efficient and continuous measures in STADA’s supply chains, purchasing, sales and marketing activities.

In 2020, STADA completed a total of seven deals, including Walmark’s acquisition of dietary supplements, minerals and vitamins in Central and Eastern Europe, a portfolio from GSK and the formerly Takeda brands in Russia and the CIS. In addition, there have been more than 80 successful licensed transactions.

“Excellent revenue and profit increase reflect the capabilities and excellent business spirit of the global STADA team. Our strategy is to position STADA as a trusted partner  in the healthcare field, specialty drugs and generics are succeeding well,” said Mr. Goldschmidt.

Top 5 in Europe

Thanks to smart acquisition strategies and impressive business results in 2020, STADA has moved up 4 ranks to the top 5 from 9th place in the European healthcare market, while maintaining 4th position in the continent’s generics market.

Consumer healthcare products and specialty drugs are STADA’s key products, accounting for about half of the group’s sales with total value of EUR 3.01 billion in 2020.

Bringing European quality to Vietnam

In the Vietnamese market, STADA Group has built a pharmaceutical site that not only meets the most stringent standards in the world pharmaceutical industry, but also has a regional production capacity.

Products with the STADA brand produced here are specialty drugs in hospitals for diseases ranging from fatal diseases to chronic and acute ones in many different specialties, with quality equivalent to European drugs.

As a result, it has become the first choice of pharmacies. STADA Vietnam’s products not only serve domestic healthcare service, but also are exported to Europe and many countries around the world.

In Vietnam, STADA said it has built up its expertise and product portfolio to provide treatments for heart disease, high cholesterol, diabetes, or products familiar to pharmacies and drugs customer like Orlistat in obesity treatment…

Talking about the Vietnamese market, CEO Goldschmidt commented: “Vietnam is one of the important growth markets in Asia, where the group wants to continue to expand in the future. The investment in PYMEPHARCO plays a big role in developing markets in Southeast Asia and neighbouring regions”.

Not only specialty drugs, STADA group is also a leader in the field of healthcare products with over-the-counter (OTC) and healthcare (CHC) groups in Europe. In early 2021, STADA is honored to be the leading corporation in business development research voted by the world’s leading magazine in this field (CHi).

STADA is committed to providing the Vietnamese market with high quality OTC and CHC products that have been widely produced and used in Europe such as: Natures Aid, Thornton & Ross (United Kingdom), Walmark (Czech Republic)…